Abstract
New gamma-lactam TACE inhibitors were designed from known MMP inhibitors. A homology model of TACE was built and examined to identify the S1' site as the key area for TACE selectivity over MMPs. Rational exploration of the P1'-S1' interactions resulted in the discovery of the 3,5-disubstituted benzyl ether as a TACE-selective P1' group. Further optimization led to the discovery of IK682 as a selective and orally bioavailable TACE inhibitor.
MeSH terms
-
ADAM Proteins
-
ADAM17 Protein
-
Administration, Oral
-
Animals
-
Biological Availability
-
Dogs
-
Hydroxamic Acids / chemical synthesis*
-
Hydroxamic Acids / chemistry
-
Hydroxamic Acids / pharmacology
-
Lactams / chemical synthesis*
-
Lactams / chemistry
-
Lactams / pharmacology
-
Matrix Metalloproteinase 3 / chemistry
-
Metalloendopeptidases / antagonists & inhibitors*
-
Models, Molecular
-
Protease Inhibitors / chemical synthesis*
-
Protease Inhibitors / chemistry
-
Protease Inhibitors / pharmacology
-
Rats
-
Rats, Sprague-Dawley
-
Structure-Activity Relationship
-
Swine
Substances
-
Hydroxamic Acids
-
IK 682
-
Lactams
-
Protease Inhibitors
-
ADAM Proteins
-
Metalloendopeptidases
-
Matrix Metalloproteinase 3
-
ADAM17 Protein
-
Adam17 protein, rat